X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
UNO (nitric oxide) is a potent molecule, naturally synthesized in the human body. It is being evaluated in phase 1 clinical trials for advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors.
Lead Product(s): Nitric Oxide
Therapeutic Area: Oncology Product Name: UNO
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2023
Details:
Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer.
Lead Product(s): Nitric Oxide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Stanford School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 24, 2023
Details:
Nitric Oxide (NO) is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions.
Lead Product(s): Nitric Oxide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
Data suggests ultra-high concentration gaseous Nitric oxide (gNO) induced both innate and adaptive immune cell populations, and a decline in immune suppressor cells, which are indicative of an anti-tumor immune response.
Lead Product(s): Nitric Oxide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022
Details:
Beyond Cancer, including those owned by Beyond Air, will use the proceeds from the private placement for the safety and efficacy of the ultra-high concentration nitric oxide product, as well as its therapeutic potential in a number of indications.
Lead Product(s): Nitric Oxide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Beyond Air
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 18, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
